FeesSafety
Pluang+

Novo Nordisk offers a strong dividend yield and growth potential, driven by diabetes and weight-loss drugs.

Market News
20 Nov 2026, 15:29 WIB
The Motley Fool
View Source
Bullish
Novo Nordisk offers a strong dividend yield and growth potential, driven by diabetes and weight-loss drugs.

Novo Nordisk stands out with a high dividend yield of 4.6%, growing steadily from $0.62 in 2019 to $1.85 per share in 2026, supported by a healthy payout ratio of 45%. The company's valuation appears attractive with a price-to-sales ratio of 3.5 and a forward P/E of 12.3, below historical averages. Novo Nordisk's business is expanding beyond diabetes treatment into weight-loss drugs, including an oral GLP-1 pill soon available in over 20 markets. Despite competition and some clinical setbacks, its promising pipeline and shareholder-friendly policies make it a compelling option for income and growth investors.

Novo Nordisk offers a notable dividend yield of 4.62%, closely matching the article's figure, highlighting its appeal for income-focused investors. On Pluang, NVO trades at USD 38.38, down 1.26% as of Nov 20, 2026 20:11 WIB, with a market cap of $171.52 billion. Despite recent selling pressure reflected in 87% sell orders, the stock remains a significant health sector player with a typical hold time of 120 days on the platform.

More News (NVO)

Novo Nordisk raises 2026 cash flow forecast, eyes cautious growth amid patent risks and competition

Novo Nordisk raises 2026 cash flow forecast, eyes cautious growth amid patent risks and competition

Novo Nordisk updated its 2026 free cash flow guidance to 60–70 billion DKK, supported by lower capital expenditure and a diversified product pipeline including the Wegovy pill. The company expects adjusted sales and operating profit to grow modestly ...

Analyst Insights
Bullish
2 days ago
Novo Nordisk raises cash flow guidance, boosts valuation on strong obesity drug growth and cost control.

Novo Nordisk raises cash flow guidance, boosts valuation on strong obesity drug growth and cost control.

Novo Nordisk has increased its free cash flow guidance to DKK 60–70 billion after reporting DKK 28.4 billion in Q3, with a gross margin improvement to 82.1%. The company's obesity drug is expanding internationally, and positive data on a lower-dose v...

Analyst Insights
Bullish
2 days ago
Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

The global anti-obesity drugs market is projected to grow from USD 8.96 billion in 2026 to USD 64.96 billion by 2035, driven by a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate the market with blockbuster drugs like Mounjaro, Zepbound, and Wegov...

Bullish
3 days ago
Wegovy trial shows significant BMI reduction in obese children aged 6-12, with no safety concerns.

Wegovy trial shows significant BMI reduction in obese children aged 6-12, with no safety concerns.

Novo's late-stage trial results reveal Wegovy significantly lowers BMI in children aged 6 to under 12 with obesity, reducing BMI by up to 19.7 percentage points compared to placebo over 68 weeks. The drug, already approved for those 12 and older, sho...

Market News
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App